MODELLING THE GREENHOUSE GAS EMISSIONS OF AN IMMUNIZATION PROGRAM AGAINST RESPIRATORY SYNCYTIAL VIRUS IN INFANTS IN THE UNITED KINGDOM
This study shows how prevention can deliver benefits to people, NHS system capacity, and the environment. However, avoided patient care pathway emissions must be considered alongside drug lifecycle emissions, which are not included here.
Authors
- Mersha Chetty
- Thierry Rigoine de Fougerolles
- Richard Hudson (ORCID: https://orcid.org/0000-0003-2661-5348)
- Flora Leadley
- Priscille de la Tour
Institutions
- Sanofi (France) (FR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- International Journal of Technology Assessment in Health Care
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1017/s0266462325100524
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Sanofi